Research programme: cancer therapeutics - Eurobio Scientific
Alternative Names: EHT-107; EHT-6706Latest Information Update: 30 Aug 2019
At a glance
- Originator ExonHit Therapeutics
- Developer Eurobio Scientific
- Class Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 05 Jul 2013 Preclincal development is ongoing in the USA